Abstract
Allogenic blood transfusion and human blood donation is a vital and necessary component of medicine and resuscitative efforts. However, it is not without risk and is subject to supply and availability. Blood transfusion performs many functions, such as volume expansion, but we have developed substitutes for a number of these functions. Unfortunately, the most important task of red blood cells is the carrying and delivery of oxygen to tissues and for this we do not have an adequate substitute. An artificial oxygen carrier that could be derived in the lab and made at will would solve many of the complications associated with transfusion medicine. Risk of infection from HIV and hepatitis C would be non-existent. Supply shortages and storage issues potentially would be a thing of the past. Transfusion reactions from ABO incompatibility would no longer pose a danger to our patients. A number of possibilities have been investigated in the past with mixed results, but there is hope and research efforts are ongoing. Despite this, currently there is no blood substitute clinically available in the U.S approved for regular use. However, some are available in other countries and attainable under certain conditions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Winslow RM. Blood substitutes, a moving target. Nature Med. 1995;1:1212–5.
Fridey JL, Silvergleid AJ, Tirnauer JS editors. Oxygen carriers as alternatives to red blood cell transfusion. Up to Date. Accessed 30 Aug 2019. https://www-uptodate-com.proxy1.lib.tju.edu/contents/oxygen-carriers-as-alternatives-to-red-blood-cell-transfusion?search=oxygen%20carriers%20as%20alternatives%20to%20red%20blood%20cell%20transfusion&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
Scott MG, Kucik DF, Goodnough LT, Monk TG. Blood substitutes: evolution and future applications. Clin Chem. 1997;43(9):1724.
Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299(19):2304. Epub 28 Apr 2008.
Szebeni J, Wassef NM, Hartman KR, Rudolph AS, Alving CR. Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion. 1997;37(2):150.
Scott MG, Kicik DF, Goodnough LT, Monk TG. Blood substitutes: evolution and future applications. Clin Chem. 1997;43(9):1724–31.
Kerins DM. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Am J Med Sci. 1994;307(3):218.
Donahue LL, Shapira I, Shander A, Kolitz J, Allen S, Greenburg G. Management of acute anemia in a Jehovah’s witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion. 2010;50(7):1561.
Mer M, Hodgson E, Wallis L, Jacobson B, Levien L, Snyman J, Sussman MJ, James M, van Gelder A, Allgaier R, Jahr JS. Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients. Transfusion. 2016;56(10):2631. Epub 2016 Sep 23
Kim HW. Acellular hemoglobin-based oxygen carrier mediated blood pressure elevation and vasoconstriction: a review of proposed mechanisms and contributing factors. In: Kim H, Greenburg A, editors. Hemoglobin-based oxygen carriers as red cell substitutes and oxygen therapeutics. Berlin/Heidelberg: Springer; 2013.
Estep TN. HBOCs and cardiac integrity. In: Kim H, Greenburg A, editors. Hemoglobin-based oxygen carriers as red cell substitutes and oxygen therapeutics. Berlin/ Heidelberg: Springer; 2013.
Jahr JS, Chung M, Anvarhosseini A, Kim HW. Effects of hemoglobin-based oxygen carriers on blood coagulation. In: Kim H, Greenburg A, editors. Hemoglobin-based oxygen carriers as red cell substitutes and oxygen therapeutics. Berlin/Heidelberg: Springer; 2013.
Smani Y. HBOC interferences with routine clinical laboratory tests. In: Kim H, Greenburg A, editors. Hemoglobin-based oxygen carriers as red cell substitutes and oxygen therapeutics. Berlin/Heidelberg: Springer; 2013.
Trakarnsanga K, Griffiths R, Wilson M, Blair A, Satchwell T, Meinders M, Cogan N, Kupzig S, Kurita R, Nakamura Y, Toye A, Anstee D, Frayne J. An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cells. Nature Communications. 2017;8:14750.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tiegs, J. (2021). Blood Substitutes and Artificial Oxygen Carriers. In: Scher, C.S., Kaye, A.D., Liu, H., Perelman, S., Leavitt, S. (eds) Essentials of Blood Product Management in Anesthesia Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-59295-0_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-59295-0_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-59294-3
Online ISBN: 978-3-030-59295-0
eBook Packages: MedicineMedicine (R0)